

GLAXOSMITHKLINE PLC
Form 6-K
July 12, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 12 July 2017

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')
Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status Chief Executive Officer
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 - b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary Shares under the Company's Share Reward Plan
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.0407	8 (partnership shares)
£16.0407	8 (matching shares)
 - d) Aggregated information
Aggregated volume Price 16 Ordinary Shares
£16.0407
 - e) Date of the transaction 2017-07-11
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global Manufacturing & Supply
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

	ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s)	Price(s) Volume(s) £16.0407 8 (partnership shares) £16.0407 8 (matching shares)
d) Aggregated information	16 Ordinary Shares
Aggregated volume Price	£16.0407
e) Date of the transaction	2017-07-11
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr S Dingemans
 - b) Position/status Chief Financial Officer
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each (‘Ordinary Shares’)
--	---

	ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s)	Price(s) Volume(s) £16.0407 8 (partnership shares) £16.0407 8 (matching shares)

d) Aggregated information	16 Ordinary Shares
Aggregated volume Price	£16.0407

e) Date of the transaction	2017-07-11
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr N Hirons
 - b) Position/status SVP, Global Ethics & Compliance
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 - b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary Shares under the Company's Share Reward Plan
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.0407	8 (partnership shares)
£16.0407	8 (matching shares)
 - d) Aggregated information

Aggregated information	16 Ordinary Shares
Aggregated volume Price	£16.0407
 - e) Date of the transaction 2017-07-11
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr S A Hussain
 - b) Position/status President, Global Pharmaceuticals
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

	ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s)	Price(s) Volume(s) £16.0407 8 (partnership shares) £16.0407 8 (matching shares)
d) Aggregated information	16 Ordinary Shares
Aggregated volume Price	£16.0407
e) Date of the transaction	2017-07-11
f) Place of the transaction	London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr D S Redfern
b) Position/status	Chief Strategy Officer
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a) Description of the financial instrument	Ordinary shares of 25 pence each (‘Ordinary Shares’)
b) Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s)	Price(s) Volume(s) £16.0407 8 (partnership shares) £16.0407 8 (matching shares)
d) Aggregated information	16 Ordinary Shares
Aggregated volume Price	£16.0407
e) Date of the transaction	2017-07-11
f) Place of the transaction	London Stock Exchange (XLON)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms C Thomas
 - b) Position/status SVP, Human Resources
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 - b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary Shares under the Company's Share Reward Plan
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.0407	8 (partnership shares)
£16.0407	8 (matching shares)
 - d) Aggregated information

Aggregated information	16 Ordinary Shares
Aggregated volume Price	£16.0407
 - e) Date of the transaction 2017-07-11
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr P C Thomson
 - b) Position/status President, Global Affairs
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 - b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary Shares under the Company's Share

Reward Plan

- | | | |
|---|--|------------------------|
| | Price(s) | Volume(s) |
| c) Price(s) and volume(s) | £16.0407 | 8 (partnership shares) |
| | £16.0407 | 8 (matching shares) |
| | | |
| d) Aggregated information | 16 Ordinary Shares | |
| Aggregated volume Price | £16.0407 | |
| | | |
| e) Date of the transaction | 2017-07-11 | |
| f) Place of the transaction | London Stock Exchange (XLON) | |
| | | |
| 1. Details of PDMR/person closely associated with them ('PCA') | | |
| a) Name | Dr P J T Vallance | |
| b) Position/status | President, R&D | |
| c) Initial notification/
amendment | Initial notification | |
| 2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor | | |
| a) Name | GlaxoSmithKline plc | |
| b) LEI | 5493000HZTVUYLO1D793 | |
| 3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each place
where transaction(s) has been conducted | | |
| a) Description of the financial instrument | Ordinary shares of 25 pence each
(‘Ordinary Shares’) | |
| | ISIN: GB0009252882 | |
| b) Nature of the transaction | Acquisition of Ordinary Shares
under the Company's Share
Reward Plan | |
| | | |
| | Price(s) | Volume(s) |
| c) Price(s) and volume(s) | £16.0407 | 8 (partnership shares) |
| | £16.0407 | 8 (matching shares) |
| | | |
| d) Aggregated information | 16 Ordinary Shares | |
| Aggregated volume Price | £16.0407 | |
| | | |
| e) Date of the transaction | 2017-07-11 | |
| f) Place of the transaction | London Stock Exchange (XLON) | |
| | | |
| 1. Details of PDMR/person closely associated with them ('PCA') | | |
| a) Name | Mrs V A Whyte | |
| b) Position/status | Company Secretary | |

- | | | |
|----|--|--|
| c) | Initial notification/
amendment | Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | GlaxoSmithKline plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | |
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') |
| b) | Nature of the transaction | ISIN: GB0009252882
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
| c) | Price(s) and volume(s) | Price(s) Volume(s)
£16.0407 8 (partnership shares)
£16.0407 8 (matching shares) |
| d) | Aggregated information
Aggregated volume Price | 16 Ordinary Shares
£16.0407 |
| e) | Date of the transaction | 2017-07-11 |
| f) | Place of the transaction | London Stock Exchange (XLON) |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: July 12, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc

